LC
KURA icon

Lindbrook Capital’s Kura Oncology KURA Stock Holding History

Lindbrook Capital’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$4.59K Buy
696
+617
+781% +$4.81K ﹤0.01% 1983
2024
Q4 		$688 Sell
79
-10
-11% -$144 ﹤0.01% 2550
2024
Q3 		$1.74K Sell
89
-118
-57% -$2.39K ﹤0.01% 2390
2024
Q2 		$4.26K Buy
207
+102
+97% +$2.1K ﹤0.01% 2073
2024
Q1 		$2.24K Buy
105
+23
+28% +$447 ﹤0.01% 2202
2023
Q4 		$1.18K Buy
+82
New +$806 ﹤0.01% 2430
2023
Q3 		– Sell
-245
Closed -$2.49K – 2762
2023
Q2 		$2.59K Sell
245
-905
-79% -$10.7K ﹤0.01% 2048
2023
Q1 		$14.1K Buy
1,150
+715
+164% +$8.92K ﹤0.01% 1244
2022
Q4 		$5.4K Sell
435
-229
-34% -$3.33K ﹤0.01% 1787
2022
Q3 		$9K Sell
664
-76
-10% -$1.17K ﹤0.01% 1376
2022
Q2 		$14K Sell
740
-59
-7% -$849 ﹤0.01% 1127
2022
Q1 		$13K Sell
799
-1,079
-57% -$15.6K ﹤0.01% 1189
2021
Q4 		$26K Buy
1,878
+1,771
+1,655% +$28.7K ﹤0.01% 929
2021
Q3 		$2K Hold
107
– – ﹤0.01% 1559
2021
Q2 		$2K Hold
107
– – ﹤0.01% 1605
2021
Q1 		$3K Hold
107
– – ﹤0.01% 1430
2020
Q4 		$3K Hold
107
– – ﹤0.01% 1344
2020
Q3 		$3K Hold
107
– – ﹤0.01% 1283
2020
Q2 		$2K Hold
107
– – ﹤0.01% 1402
2020
Q1 		$1K Buy
+107
New +$1.23K ﹤0.01% 1490

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's KURA Position: Q1 2025 in Review

Lindbrook Capital increased its Kura Oncology (KURA) stake by 781% in Q1 2025, buying an estimated $4.81K and bringing the position to 696 shares worth $4.59K. The position accounts for ﹤0.01% of the portfolio, ranked #1983.

Lindbrook Capital first reported a position in KURA in Q1 2020 and has held it in 20 quarters since. The position peaked at $26K in Q4 2021. 183 funds tracked by Wall St. Rank hold KURA as of Q1 2025.

  • Lindbrook Capital held 696 shares of Kura Oncology worth $4.59K as of Q1 2025.
  • Lindbrook Capital bought 617 Kura Oncology shares in Q1 2025, an estimated $4.81K.
  • Kura Oncology made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1983 holding.
  • Lindbrook Capital first reported a position in Kura Oncology in Q1 2020 and has held it in 20 quarters since.
  • Lindbrook Capital's Kura Oncology position peaked at $26K in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.